These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 38945959)

  • 1. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
    Thorel L; Perréard M; Florent R; Divoux J; Coffy S; Vincent A; Gaggioli C; Guasch G; Gidrol X; Weiswald LB; Poulain L
    Exp Mol Med; 2024 Jul; 56(7):1531-1551. PubMed ID: 38945959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
    Mei J; Liu X; Tian HX; Chen Y; Cao Y; Zeng J; Liu YC; Chen Y; Gao Y; Yin JY; Wang PY
    Clin Transl Med; 2024 Apr; 14(4):e1656. PubMed ID: 38664597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patient-derived tumor organoids (or tumoroid), a growing preclinical model for oncology].
    Thorel L; Florent R; Perréard M; Vincent A; Poulain L; Weiswald LB
    Med Sci (Paris); 2022 Nov; 38(11):880-887. PubMed ID: 36448893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Organoids: The Era of Personalized Medicine.
    Rassomakhina NV; Ryazanova AY; Likhov AR; Bruskin SA; Maloshenok LG; Zherdeva VV
    Biochemistry (Mosc); 2024 Jan; 89(Suppl 1):S127-S147. PubMed ID: 38621748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor organoids: Opportunities and challenges to guide precision medicine.
    Veninga V; Voest EE
    Cancer Cell; 2021 Sep; 39(9):1190-1201. PubMed ID: 34416168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patient-derived tumor organoids (or tumoroid) as valuable precision medicine tools].
    Perréard M; Florent R; Thorel L; Vincent A; Weiswald LB; Poulain L
    Med Sci (Paris); 2022 Nov; 38(11):888-895. PubMed ID: 36448894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical models for precision oncology.
    Ibarrola-Villava M; Cervantes A; Bardelli A
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):239-246. PubMed ID: 29959990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoids: An intermediate modeling platform in precision oncology.
    Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
    Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in patient-derived tumor organoids for reconstructing TME of head and neck cancer.
    Chen L; Chen Y; Ge L; Zhang Q; Meng J
    J Oral Pathol Med; 2024 Apr; 53(4):238-245. PubMed ID: 38561906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for generation of and high-throughput drug testing with patient-derived colorectal cancer organoids.
    Tan T; Mouradov D; Gibbs P; Sieber OM
    STAR Protoc; 2024 Jun; 5(2):103090. PubMed ID: 38809757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.
    Vivarelli S; Candido S; Caruso G; Falzone L; Libra M
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal Cancer.
    van der Graaff D; Seghers S; Vanclooster P; Deben C; Vandamme T; Prenen H
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation patient derived tumor organoids.
    Podaza E; Kuo HH; Nguyen J; Elemento O; Martin ML
    Transl Res; 2022 Dec; 250():84-97. PubMed ID: 35964899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
    Divoux J; Florent R; Jacobs M; Lequesne J; Grellard JM; San C; Grossi S; Kerdja K; Clarisse B; Boudier G; Cherifi F; Briand M; Dolivet E; Johnson A; Dubois B; Harter V; Lacroix J; Raboutet C; Marie B; Rousseau N; Blanc-Fournier C; Vaur D; Figeac M; Poulain L; Weiswald LB; Emile G
    BMC Cancer; 2023 Sep; 23(1):883. PubMed ID: 37726786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Spheroids to organoids: Solid cancer models for anticancer drug discovery].
    Alzeeb G; Corcos L; Le Jossic-Corcos C
    Bull Cancer; 2022 Jan; 109(1):49-57. PubMed ID: 34848046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling rectal cancer to advance neoadjuvant precision therapy.
    Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
    Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune organoids: from tumor modeling to precision oncology.
    Dao V; Yuki K; Lo YH; Nakano M; Kuo CJ
    Trends Cancer; 2022 Oct; 8(10):870-880. PubMed ID: 35773148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
    Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
    Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promises and challenges of patient-derived tumor organoids in drug development and precision oncology.
    Granat LM; Kambhampati O; Klosek S; Niedzwecki B; Parsa K; Zhang D
    Animal Model Exp Med; 2019 Sep; 2(3):150-161. PubMed ID: 31773090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.